Literature DB >> 22886041

Extension of NPDE for evaluation of nonlinear mixed effect models in presence of data below the quantification limit with applications to HIV dynamic model.

Thi Huyen Tram Nguyen1, Emmanuelle Comets, France Mentré.   

Abstract

Data below the quantification limit (BQL data) are a common challenge in data analyses using nonlinear mixed effect models (NLMEM). In the estimation step, these data can be adequately handled by several reliable methods. However, they are usually omitted or imputed at an arbitrary value in most evaluation graphs and/or methods. This can cause trends to appear in diagnostic graphs, therefore, confuse model selection and evaluation. We extended in this paper two metrics for evaluating NLMEM, prediction discrepancies (pd) and normalised prediction distribution errors (npde), to handle BQL data. For a BQL observation, the pd is randomly sampled in a uniform distribution over the interval from 0 to the probability of being BQL predicted by the model, estimated using Monte Carlo (MC) simulation. To compute npde in presence of BQL observations, we proposed to impute BQL values in both validation dataset and MC samples using their computed pd and the inverse of the distribution function. The imputed dataset and MC samples contain original data and imputed values for BQL data. These data are then decorrelated using the mean and variance-covariance matrix to compute npde. We applied these metrics on a model built to describe viral load obtained from 35 patients in the COPHAR 3-ANRS 134 clinical trial testing a continued antiretroviral therapy. We also conducted a simulation study inspired from the real model. The proposed metrics show better behaviours than naive approaches that discard BQL data in evaluation, especially when large amounts of BQL data are present.

Entities:  

Mesh:

Year:  2012        PMID: 22886041     DOI: 10.1007/s10928-012-9264-2

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  23 in total

1.  Identification of significant host factors for HIV dynamics modelled by non-linear mixed-effects models.

Authors:  Hulin Wu; Lang Wu
Journal:  Stat Med       Date:  2002-03-15       Impact factor: 2.373

2.  Analysis of toxicokinetic data using NONMEM: impact of quantification limit and replacement strategies for censored data.

Authors:  J P Hing; S G Woolfrey; D Greenslade; P M Wright
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-10       Impact factor: 2.745

3.  Mixed effects models with censored data with application to HIV RNA levels.

Authors:  J P Hughes
Journal:  Biometrics       Date:  1999-06       Impact factor: 2.571

4.  Impact of omission or replacement of data below the limit of quantification on parameter estimates in a two-compartment model.

Authors:  Vincent Duval; Mats O Karlsson
Journal:  Pharm Res       Date:  2002-12       Impact factor: 4.200

5.  Likelihood based approaches to handling data below the quantification limit using NONMEM VI.

Authors:  Jae Eun Ahn; Mats O Karlsson; Adrian Dunne; Thomas M Ludden
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-08-07       Impact factor: 2.745

6.  Evaluations of Bayesian and maximum likelihood methods in PK models with below-quantification-limit data.

Authors:  Shuying Yang; James Roger
Journal:  Pharm Stat       Date:  2010 Oct-Dec       Impact factor: 1.894

7.  A new exact test for the evaluation of population pharmacokinetic and/or pharmacodynamic models using random projections.

Authors:  Celine Marielle Laffont; Didier Concordet
Journal:  Pharm Res       Date:  2011-04-14       Impact factor: 4.200

8.  Estimation of population characteristics of pharmacokinetic parameters from routine clinical data.

Authors:  L B Sheiner; B Rosenberg; V V Marathe
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

9.  HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time.

Authors:  A S Perelson; A U Neumann; M Markowitz; J M Leonard; D D Ho
Journal:  Science       Date:  1996-03-15       Impact factor: 47.728

10.  Relationships between antiviral treatment effects and biphasic viral decay rates in modeling HIV dynamics.

Authors:  A A Ding; H Wu
Journal:  Math Biosci       Date:  1999-08       Impact factor: 2.144

View more
  12 in total

1.  Individual Bayesian Information Matrix for Predicting Estimation Error and Shrinkage of Individual Parameters Accounting for Data Below the Limit of Quantification.

Authors:  Thi Huyen Tram Nguyen; Thu Thuy Nguyen; France Mentré
Journal:  Pharm Res       Date:  2017-06-28       Impact factor: 4.200

2.  Improvement of Parameter Estimations in Tumor Growth Inhibition Models on Xenografted Animals: a Novel Method to Handle the Interval Censoring Caused by Measurement of Smaller Tumors.

Authors:  Philippe B Pierrillas; Michel Tod; Magali Amiel; Marylore Chenel; Emilie Henin
Journal:  AAPS J       Date:  2016-01-12       Impact factor: 4.009

3.  Development and performance of npde for the evaluation of time-to-event models.

Authors:  M Cerou; M Lavielle; K Brendel; M Chenel; E Comets
Journal:  Pharm Res       Date:  2018-01-09       Impact factor: 4.200

4.  Population Pharmacokinetic Model of Oxfendazole and Metabolites in Healthy Adults following Single Ascending Doses.

Authors:  Thanh Bach; Daryl J Murry; Larissa V Stebounova; Gregory Deye; Patricia Winokur; Guohua An
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

5.  Neutrophil dynamics in peritoneal carcinomatosis patients treated with cytoreductive surgery and hyperthermic intraperitoneal oxaliplatin.

Authors:  Carlos Pérez-Ruixo; Belén Valenzuela; José Esteban Peris; Pedro Bretcha-Boix; Vanesa Escudero-Ortiz; José Farré-Alegre; Juan José Pérez-Ruixo
Journal:  Clin Pharmacokinet       Date:  2013-12       Impact factor: 6.447

6.  Maturation of Oxycodone Pharmacokinetics in Neonates and Infants: a Population Pharmacokinetic Model of Three Clinical Trials.

Authors:  Pyry Välitalo; Merja Kokki; Veli-Pekka Ranta; Klaus T Olkkola; Andrew C Hooker; Hannu Kokki
Journal:  Pharm Res       Date:  2017-02-15       Impact factor: 4.200

7.  What to Do About Missed Doses? A Retrospective Study of Olanzapine in the Elderly.

Authors:  Tao Xiao; Zhanzhang Wang; Guanlie Li; Shanqing Huang; Xiuqing Zhu; Shujing Liu; Xiaolin Li; Jinqing Hu; Dewei Shang; Yuguan Wen
Journal:  Drug Des Devel Ther       Date:  2021-08-04       Impact factor: 4.162

8.  Platelet Dynamics in Peritoneal Carcinomatosis Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Oxaliplatin.

Authors:  Carlos Pérez-Ruixo; Belén Valenzuela; José Esteban Peris; Pedro Bretcha-Boix; Vanesa Escudero-Ortiz; José Farré-Alegre; Juan José Pérez-Ruixo
Journal:  AAPS J       Date:  2015-11-17       Impact factor: 4.009

9.  Population Pharmacokinetics of AL-335 and Its Two Main Metabolites (ALS-022399, ALS-022227) in Monotherapy and in Combination with Odalasvir and/or Simeprevir.

Authors:  Elodie Valade; Thomas N Kakuda; Matthew W McClure; Christopher Westland; Belén Valenzuela; Sivi Ouwerkerk-Mahadevan; Juan José Perez-Ruixo; Oliver Ackaert
Journal:  AAPS J       Date:  2018-10-24       Impact factor: 4.009

10.  Use of normalized prediction distribution errors for assessing population physiologically-based pharmacokinetic model adequacy.

Authors:  Anil R Maharaj; Huali Wu; Christoph P Hornik; Antonio Arrieta; Laura James; Varsha Bhatt-Mehta; John Bradley; William J Muller; Amira Al-Uzri; Kevin J Downes; Michael Cohen-Wolkowiez
Journal:  J Pharmacokinet Pharmacodyn       Date:  2020-04-22       Impact factor: 2.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.